Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A biologically active complex comprising a polypeptide having the sequence of a naturally occurring protein or a variant thereof, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein for example as a result of a modification of at least one cysteine residue; or a peptide of up to 50 amino acids; and a fatty acid or lipid or a salt thereof, for use in prophylactic treatment of cancers, in particular of the gastrointestinal tract. Compositions that may comprise the complex and have use as nutraceuticals are obtainable from milk or milk fractions and form a further aspect of the invention. Methods of treatment in particular for the prevention of cancer form a further aspect of the invention.

Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, which gives rise to opportunities for the development of further active agents and screening methods.

Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, that gives rise to opportunities for the development of further active agents and screening methods.

Abstract: A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of ?-lactalbumin, such as human ?-lactalbumin or a fragment thereof but which lacks intra-molecular disulfide bonds, and oleic acid, and process for preparing this are described and claimed. The recombinant protein suitably has cysteines found in the native protein changed to other amino acids, such as alanine. Improvements in recombinant expression, process rationalisation and yields of biologically active complexes, as well as the complexes obtained are also described and claimed.

Abstract: A biologically active complex comprising either a polypeptide having the sequence of a variant of a naturally occurring protein, wherein said polypeptide is at least partially unfolded as compared to the said naturally occurring protein; or a peptide of up to 50 amino acids, for instance a fragment of the naturally occurring protein or a variant thereof; and a pharmaceutically acceptable salt of a fatty acid or lipid. The complexes of the invention demonstrate a novel mode of action, that gives rise to opportunities for the development of further active agents and screening methods.

Abstract: A method for preparing a biologically active complex, said method comprising a recombinant protein having the sequence of ?-lactalbumin, such as human ?-lactalbumin or a fragment thereof but which lacks intra-molecular disulfide bonds, and oleic acid, and process for preparing this are described and claimed. The recombinant protein suitably has cysteines found in the native protein changed to other amino acids, such as alanine. Improvements in recombinant expression, process rationalisation and yields of biologically active complexes, as well as the complexes obtained are also described and claimed.

Abstract: The use of a biologically active complex of ?-lactalbumin, selected from HAMLET (human ?-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous papillomas.

Abstract: A method for producing an oligomeric form of ?-lactalbumin which is in the molten globule-like state is described. The method suitably comprises exposing a source of ?-lactalbumin in which the ?-lactalbumin is preferably in the molten globule-like state, to an ion exchange medium which has been pre-treated with casein or an active component thereof, such as oleic acid, and recovering ?-lactalbumin in an oligomeric form therefrom. Pre-treatment of the ion exchange medium, particularly with casein derived from human milk, has been found to significantly improve yields of the oligomeric form of ?-lactalbumin and mean that it can readily isolated from readily available sources such as bovine ?-lactalbumin. This form of ?-lactalbumin is useful therapeutically, in particular as an antibacterial agent and also as an anti-cancer therapeutic.

Abstract: A combination of component (i) which is HAMLET or a biologically active modification thereof, or a biologically active fragment of either of these, and component (ii) which is a histone deacetylase (HDAC) inhibitor. This combination shows synergistic effects in the treatment of for example proliferative diseases such as those which produce tumours.

Abstract: The use of a biologically active complex of ?-lactalbumin, selected from HAMLET (human ?-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous papillomas.

Abstract: The use of a biologically active complex of ?-lactalbumin, selected from HAMLET (human ?-lactalbumin made lethal to tumour cells) or a biologically active modification thereof, or a biologically active fragment of either of these, in the preparation of a medicament for use in the treatment of papilloma, such as cutaneous papillomas.

Abstract: The present invention relates to the use of alpha-lactalbumin in the preparation of preparations to be used in therapeutic or prophylactic treatment and/or for diagnostic use for infections, preferably of the respiratory tract, caused by bacteria, in particular S. pneumoniae and/or H. influenzae. The present invention further relates to essentially pure protein complexes comprising alpha-lactalbumin and the use of these protein complexes for therapeutically or prophylactically treating a bacterial infection, especially infections of the respiratory tract caused by S. pneumoniae and/or H. influenzae.

Abstract: A method for producing an oligomeric form of ?-lactalbumin which is in the molten globule-like state is described. The method suitably comprises exposing a source of ?-lactalbumin in which the ?-lactalbumin is preferably in the molten globule-like state, to an ion exchange medium which has been pre-treated with casein or an active component thereof, such as oleic acid, and recovering ?-lactalbumin in an oligomeric form therefrom. Pre-treatment of the ion exchange medium, particularly with casein derived from human milk, has been found to significantly improve yields of the oligomeric form of ?-lactalbumin and means that it can be readily isolated from readily available sources such as bovine ?-lactalbumin. This form of ?-lactalbumin is useful therapeutically, in particular as an antibacterial agent and also as an anti-cancer therapeutic.